Matt is the Chairman of the Board of Directors at Addition. He previously served as Executive Chairman from October 2024 to May 2025.  Matt is an executive with more than 30 years of experience in the research, development, and commercialization of innovative therapeutics.  He also currently serves as Chairman of the Board of Directors at Remix Therapeutics, Inc., Chairman of the Board of Directors at Rezo Therapeutics, Inc. and is a Venture Partner with SR One.  In 2012 Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception until its acquisition by Astellas Pharma Inc. in January 2020. Previously Matt worked for Genzyme Corporation, BioMarin Pharmaceutical, Amicus Therapeutics, and Iris Medicine. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, from 2015-2021, and was Chairman in 2019 and 2020.  Mr. Patterson received his Bachelor’s degree in Biochemistry from Bowdoin College.